An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors
Public ClinicalTrials.gov record NCT02488759. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherapy and Nivolumab Combination Therapy in Subjects With Virus-Positive and Virus-Negative Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study to investigate the safety and effectiveness of nivolumab, and nivolumab combination therapy, to treat patients who have virus-associated tumors. Certain viruses have been known to play a role in tumor formation and growth. This study will investigate the effects of the study drugs, in patients who have the following types of tumors: * Anal canal cancer-No longer enrolling this tumor type * Cervical cancer * Epstein Barr Virus (EBV) positive gastric cancer-No longer enrolling this tumor type * Merkel Cell Cancer * Penile cancer-No longer enrolling this tumor type * Vaginal and vulvar cancer-No longer enrolling this tumor type * Nasopharyngeal Cancer - No longer enrolling this tumor type * Head and Neck Cancer - No longer enrolling this tumor type
Study identification
- NCT ID
- NCT02488759
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 578 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 12, 2015
- Primary completion
- Mar 18, 2021
- Completion
- Oct 23, 2022
- Last update posted
- Nov 12, 2023
2015 – 2022
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0033 | Tampa | Florida | 33612-9497 | — |
| Local Institution - 0003 | Atlanta | Georgia | 30322 | — |
| Local Institution - 0023 | Lutherville | Maryland | 21093 | — |
| Local Institution - 0002 | Boston | Massachusetts | 02114 | — |
| Local Institution - 0019 | Boston | Massachusetts | 02114 | — |
| Local Institution - 0020 | Boston | Massachusetts | 02114 | — |
| Local Institution - 0035 | Ann Arbor | Michigan | 48109 | — |
| Local Institution - 0036 | New York | New York | 10065 | — |
| Local Institution - 0022 | Charlotte | North Carolina | 28204 | — |
| Local Institution - 0005 | Oklahoma City | Oklahoma | 73104 | — |
| Local Institution - 0004 | Portland | Oregon | 97213 | — |
| Local Institution - 0029 | Pittsburgh | Pennsylvania | 15232 | — |
| Local Institution - 0001 | Sioux Falls | South Dakota | 57104 | — |
| Local Institution - 0021 | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
Recently updated Various Advanced Cancer trials
Other public records listing Various Advanced Cancer. Sorted by last update posted; newest first. Not a recommendation.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02488759, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 12, 2023 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02488759 live on ClinicalTrials.gov.